KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Liabilities (2016 - 2026)

Gsk has reported Total Liabilities over the past 18 years, most recently at -$61.3 billion for Q1 2026.

  • For Q1 2026, Total Liabilities fell 3.39% year-over-year to -$61.3 billion; the TTM value through Mar 2026 reached -$61.3 billion, down 3.39%, while the annual FY2025 figure was -$60.1 billion, 200.92% down from the prior year.
  • Total Liabilities for Q1 2026 was -$61.3 billion at Gsk, down from -$60.1 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $59.5 billion in Q4 2024 and troughed at -$83.6 billion in Q2 2022.
  • A 5-year average of -$37.9 billion and a median of -$59.2 billion in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 69.01% in 2022 and later tumbled 200.92% in 2025.
  • Year by year, Total Liabilities stood at $58.7 billion in 2022, then dropped by 2.3% to $57.4 billion in 2023, then increased by 3.79% to $59.5 billion in 2024, then crashed by 200.92% to -$60.1 billion in 2025, then decreased by 1.99% to -$61.3 billion in 2026.
  • Business Quant data shows Total Liabilities for GSK at -$61.3 billion in Q1 2026, -$60.1 billion in Q4 2025, and -$61.5 billion in Q3 2025.